drug · small molecule

VAFSEO

updated 3mo ago

by $AKBA Akebia Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Egl nine homolog 1Prolyl hydroxylase EGLN2Prolyl hydroxylase EGLN3

all catalysts(0)

nothing on the calendar yet

Trials studying VAFSEO

phase3Vafseo Outcomes In-Center Experienceactive not recruitingn=2,200
phase3To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysisactive not recruitingn=353
phase3Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agentswithdrawn
phase3Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Diseasewithdrawn
phase3Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)completedn=319
phase3Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjectscompletedn=456

News(0)

no news has mentioned this drug yet

brand

VAFSEO

trade names

Vafseo

generic

VADADUSTAT

MOA

12.1 Mechanism of Action Vadadustat is a reversible inhibitor of HIF-prolyl-4-hydroxylases (PH)1, PH2, and PH3 (IC 50 in the nM range). This activity results in the stabilization and nuclear accumulation of HIF-1α and HIF-2α transcription factors, and increased production of erythropoietin (EPO).

indication

1 INDICATIONS AND USAGE VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia In patients with anemia due to CKD not on dialysis [see Warnings and Precautions ( 5.6 )] . VAFSEO is a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. ( 1 ) Limitations of Use Not been shown to improve quality of life, fatigue, or patient well-being. Not indicated for use: As a substitute for transfusion in patients requiring immediate correction of anemia. ( 1 ) In patients with anemia due to CKD not on dialysis. ( 1 , 5.6 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 4m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

VAFSEO

updated 3mo ago

by $AKBA Akebia Therapeutics, Inc.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Egl nine homolog 1Prolyl hydroxylase EGLN2Prolyl hydroxylase EGLN3

all catalysts(0)

nothing on the calendar yet

Trials studying VAFSEO

News(0)

no news has mentioned this drug yet

brand

VAFSEO

trade names

Vafseo

generic

VADADUSTAT

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 4m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

VAFSEO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VAFSEO

News(0)

Report a data issue

comments(0)

VAFSEO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying VAFSEO

News(0)

Report a data issue

comments(0)